Iveric Bio Inc (ISEE) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ISEE quarterly Cash Flow →
Cash flow data covering Iveric Bio Inc–Dec 31 2018 offers a view into how Dec 31 2022's cash position has developed alongside business activity.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2022)
12 Months
(Dec 31 2021) (Dec 31 2020) (Dec 31 2019) (Dec 31 2018)
Operating Activities
Income-185.21
Depreciation & amortization0.14
Amortization of Other Assets0.47
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation26.68
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Fair Value Adjustment Related To Investor Rights Liability-
Investment Income Net Amortization Of Discount And Premium-0.62
Increase Decrease In Contract With Customer Asset-
Increase Decrease In Accrued Research And Development-2.85
Gain On Extinguishment Of Royalty Liability-
Share Based Payment Arrangement Noncash Expense In Connection With License Acquisition-
Increase Decrease In Working Capital-0.03
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accrued Interest Receivable, Net0.30
Increase (Decrease) in Accounts Payable and Accrued Liabilities9.99
Increase (Decrease) in Interest Payable, Net0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-12.62
Discontinued operations0.00
Net Cash flow from Operating Activities-163.77
Investing Activities
Capital Expenditures-0.74
Sale of Capital Items0.50
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities181.00
Payments to Acquire Marketable Securities-231.04
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-50.28
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-3.90
Long-term debt - borrowings100.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net61.89
Proceeds From Repayments Of Venture Debt Facility-
Proceeds From Follow On Public Offering Net-
Proceeds From Stock Options And Warrants Exercised8.51
Proceeds From Stock Option And Employee Stock Purchase Plan Exercises-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents261.45
Stock Issued-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability0.95
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities428.91
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-164.01
Total Cash Flow214.86
4 historic quarters locked

Sign in to unlock the full Iveric Bio Inc cash flow history.

About Iveric Bio Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001410939-23-000064

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document





                    
Get the full CSIMarket dataset: Subscribe API License